Literature DB >> 30105152

Author response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.

Brian D Berman1, Trevor Hawkins1.   

Abstract

Entities:  

Year:  2018        PMID: 30105152      PMCID: PMC6075990          DOI: 10.1212/CPJ.0000000000000470

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  2 in total

1.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Authors:  Jeffrey Cummings; Stuart Isaacson; Roger Mills; Hilde Williams; Kathy Chi-Burris; Anne Corbett; Rohit Dhall; Clive Ballard
Journal:  Lancet       Date:  2013-11-01       Impact factor: 79.321

Review 2.  Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.

Authors:  Trevor Hawkins; Brian D Berman
Journal:  Neurol Clin Pract       Date:  2017-04
  2 in total
  1 in total

Review 1.  Anesthetic Considerations for Patients on Psychotropic Drug Therapies.

Authors:  Monica W Harbell; Catalina Dumitrascu; Layne Bettini; Soojie Yu; Cameron M Thiele; Veerandra Koyyalamudi
Journal:  Neurol Int       Date:  2021-11-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.